Published in Nat Rev Microbiol on September 25, 2017
Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol (2004) 18.85
Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 13.46
The biofilm matrix. Nat Rev Microbiol (2010) 12.60
STING is a direct innate immune sensor of cyclic di-GMP. Nature (2011) 6.44
Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature (2013) 3.69
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature (2017) 3.28
Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci U S A (2005) 3.26
Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature (2010) 2.85
Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol (2009) 2.52
The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol (2008) 2.47
Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal. Nat Rev Microbiol (2011) 2.45
DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis (2013) 2.29
The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest (2007) 2.26
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. Nat Microbiol (2016) 2.16
Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat Rev Microbiol (2013) 2.04
Pseudomonas biofilm matrix composition and niche biology. FEMS Microbiol Rev (2012) 2.00
Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med (2012) 1.92
Biofilm dispersal of community-associated methicillin-resistant Staphylococcus aureus on orthopedic implant material. J Orthop Res (2010) 1.81
The in vivo biofilm. Trends Microbiol (2013) 1.79
Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol (2009) 1.78
A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis (2013) 1.76
EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci Transl Med (2014) 1.67
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros (2011) 1.65
Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol (2011) 1.54
Low levels of β-lactam antibiotics induce extracellular DNA release and biofilm formation in Staphylococcus aureus. MBio (2012) 1.51
Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc Natl Acad Sci U S A (2015) 1.48
Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother (2011) 1.46
Biomaterial-associated infection: locating the finish line in the race for the surface. Sci Transl Med (2012) 1.44
How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev (2012) 1.38
Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. J Cyst Fibros (2011) 1.36
Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol (2009) 1.36
Living in the matrix: assembly and control of Vibrio cholerae biofilms. Nat Rev Microbiol (2015) 1.25
ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect (2015) 1.24
Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun (2011) 1.24
Quorum sensing signal-response systems in Gram-negative bacteria. Nat Rev Microbiol (2016) 1.22
Ferrous iron is a significant component of bioavailable iron in cystic fibrosis airways. MBio (2013) 1.22
Multi-stimuli responsive macromolecules and their assemblies. Chem Soc Rev (2013) 1.21
D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol (2015) 1.17
Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol (2014) 1.17
Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev (2014) 1.16
Giving structure to the biofilm matrix: an overview of individual strategies and emerging common themes. FEMS Microbiol Rev (2015) 1.16
Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med (2012) 1.15
Identification of small molecules that antagonize diguanylate cyclase enzymes to inhibit biofilm formation. Antimicrob Agents Chemother (2012) 1.14
Biofilms: an emergent form of bacterial life. Nat Rev Microbiol (2016) 1.13
Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol (2016) 1.12
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) (2013) 1.11
Species-specific engineered antifouling topographies: correlations between the settlement of algal zoospores and barnacle cyprids. Biofouling (2007) 1.11
Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano (2012) 1.08
Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev (2014) 1.07
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax (2013) 1.06
Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic Di-GMP level in the bacteria. Infect Immun (2013) 1.04
Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob Agents Chemother (2012) 1.02
Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother (2014) 1.02
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release (2014) 1.01
Neutrophil extracellular traps and bacterial biofilms in middle ear effusion of children with recurrent acute otitis media--a potential treatment target. PLoS One (2013) 0.99
Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials (2013) 0.98
Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog (2014) 0.97
Extracellular DNA as a target for biofilm control. Curr Opin Biotechnol (2014) 0.97
Real-time microsensor measurement of local metabolic activities in ex vivo dental biofilms exposed to sucrose and treated with chlorhexidine. Appl Environ Microbiol (2010) 0.96
High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother (2014) 0.96
The biogeography of polymicrobial infection. Nat Rev Microbiol (2015) 0.96
Extracellular DNA within a nontypeable Haemophilus influenzae-induced biofilm binds human beta defensin-3 and reduces its antimicrobial activity. J Innate Immun (2012) 0.94
Insulin treatment modulates the host immune system to enhance Pseudomonas aeruginosa wound biofilms. Infect Immun (2013) 0.94
Novel antibiofilm chemotherapy targets exopolysaccharide synthesis and stress tolerance in Streptococcus mutans to modulate virulence expression in vivo. Antimicrob Agents Chemother (2012) 0.94
Chemorepulsion from the Quorum Signal Autoinducer-2 Promotes Helicobacter pylori Biofilm Dispersal. MBio (2015) 0.94
Nitric oxide: a key mediator of biofilm dispersal with applications in infectious diseases. Curr Pharm Des (2015) 0.93
What's on the Outside Matters: The Role of the Extracellular Polymeric Substance of Gram-negative Biofilms in Evading Host Immunity and as a Target for Therapeutic Intervention. J Biol Chem (2016) 0.93
Current applications of nanoparticles in infectious diseases. J Control Release (2016) 0.93
Bioinspired super-wettability from fundamental research to practical applications. Angew Chem Int Ed Engl (2015) 0.92
Bacterial retention on superhydrophobic titanium surfaces fabricated by femtosecond laser ablation. Langmuir (2011) 0.92
Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Rev Anti Infect Ther (2012) 0.91
The effect of arginine on oral biofilm communities. Mol Oral Microbiol (2013) 0.90
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2008) 0.90
Involvement of iron in biofilm formation by Staphylococcus aureus. PLoS One (2012) 0.89
Current Developments in Antimicrobial Surface Coatings for Biomedical Applications. Curr Med Chem (2015) 0.88
Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. J Control Release (2015) 0.87
Cephalosporin-3'-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem Int Ed Engl (2012) 0.86
Biofilm Antimicrobial Susceptibility Increases With Antimicrobial Exposure Time. Clin Orthop Relat Res (2016) 0.86
Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics (2016) 0.86
Pulse lavage is inadequate at removal of biofilm from the surface of total knee arthroplasty materials. J Arthroplasty (2013) 0.86
Cyclic di-AMP mediates biofilm formation. Mol Microbiol (2015) 0.86
Viscoelasticity of biofilms and their recalcitrance to mechanical and chemical challenges. FEMS Microbiol Rev (2015) 0.86
L-arginine destabilizes oral multi-species biofilm communities developed in human saliva. PLoS One (2015) 0.86
pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence. ACS Nano (2015) 0.85
Biofilm formation capability of Enterococcus faecalis cells in starvation phase and its susceptibility to sodium hypochlorite. J Endod (2010) 0.85
Review of nanomaterials in dentistry: interactions with the oral microenvironment, clinical applications, hazards, and benefits. ACS Nano (2015) 0.85
Antibodies against the majority subunit of type IV Pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media. Mol Microbiol (2015) 0.85
Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta (2015) 0.85
Biofilm removal by 6% sodium hypochlorite activated by different irrigation techniques. Int Endod J (2013) 0.84
Effect of nitroxides on swarming motility and biofilm formation, multicellular behaviors in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.84
Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms. Sci Adv (2016) 0.84
An engineered micropattern to reduce bacterial colonization, platelet adhesion and fibrin sheath formation for improved biocompatibility of central venous catheters. Clin Transl Med (2015) 0.83
Persister cells in biofilm associated infections. Adv Exp Med Biol (2015) 0.83
A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model. Antimicrob Agents Chemother (2016) 0.82
Synthesis of TiO2 nanotubes with ZnO nanoparticles to achieve antibacterial properties and stem cell compatibility. Nanoscale (2014) 0.82
Contribution of stress responses to antibiotic tolerance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2015) 0.82
The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa. Pathog Dis (2014) 0.82
Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J Antimicrob Chemother (2015) 0.82
Iron is a signal for Stenotrophomonas maltophilia biofilm formation, oxidative stress response, OMPs expression, and virulence. Front Microbiol (2015) 0.82